Author: admin

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about venetoclax (ABT-199), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in chronic lymphocytic leukemia (CLL) cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. Prof. Wierda also discusses the clinical trials and side-effects associated with this drug.Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.         bcl-2 inhibitor, chronic lymphocytic leukemia (cll), cll, american society of…

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the need to improve the education of physicians in order to better understand the characteristics of new treatment approaches in clinical practice.

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Stephen Nimer, MD, from Memorial Sloan-Kettering Cancer Center, New York, NY, reviews promising epigenetic targets in cancer and explains that combining epigenetic therapies with immunotherapies may improve outcomes for patients.

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the side-effects profile of novel drugs in chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Ibrutinib (trade name Imbruvica) and idelalisib are effective at controlling the disease, but occasionally, patients do have to interrupt treatment due to side-effects. Less toxic drugs, within the same category in respect to mechanism of action, have been developed and are currently being tested in clinical trials.

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about the importance of prognostic factors in the treatment of chronic lymphocytic leukemia (CLL). The most important tool to assess prognostic factors is fluorescence in situ hybridization (FISH), which is used when patients first need treatment and for any subsequent treatments, as patients can acquire chromossomal abnormalities as the disease progresses. Certain chromossomal changes, such as IgVH mutations, are important in the context of clinical trials, as they are directly associated with prognosis.

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX talks about recent advances in the treatment of chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. New drugs, and new treatment strategies are having an impact on the standard of care in the field of CLL, and clinicians are now faced with a variety of treatment options that need to be tailored for each patient.

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR talks about gene expression analysis in multiple myeloma (MM), which can help determine the prognosis of the disease based on different molecular sub-groups. The Arkansas group has developed a simple test that can help identify the genetic markers of high-risk MM, called Mymap. The data was presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss several topics related to chronic lymphocytic leukemia (CLL). The topics covered range from: ASH 2015 highlights; Bcl-2-targeted therapies; Resonate-2 clinical trial; implications and challenges of long-term therapy; venetoclax (ABT-199); combination therapies; and other related topics.

Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the future of multiple myeloma (MM) treatment. Dr Morgan believes that newly diagnosed patients will receive a drug combination that will be able to overcome the intra-clonal heterogeneity and eradicate high-risk sub-clones that lead to early relapse. To achieve this, we need to have novel end-points that can be applied early in the disease process that are surrogates for long-term outcome and perhaps minimum residual disease detachment is one of those surrogates. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting,…

Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the Phase IIIb GREEN clinical trial, of obinutuzumab (GA101) plus bendamustine in chronic lymphocytic leukemia (CLL) patients, presented at the American Society of Hematology (ASH) 2015 Annual Meeting. Patients in this arm had a complete remission rate of 40%, and the majority of them achieved minimum residual disease (MRD) negativity in the blood and approx. 50% were MRD negative in the bone marrow.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses how FLT3 occurs in about a third of adult AML patients and may prove very important at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses phase III RATIFY trial 7+3 chemo plus Midostaurin or placebo in FLT3 mutated AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses Quizartinib FLT3 inhibitor status at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the fact that no data for FLT3 inhibitor more effective than dirty inhibitor like Midostaurin in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses IDH1 and IDH2 results in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses DNMT3A and the impact on the course of AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Hagop Kantarjian, MD of MD Anderson Cancer Center discusses the new targetable molecular abnormalities in AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, explains the current approach, including some of the challenges, to the management of patients who become pregnant during or after breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses a phase 1b trial that was designed to evaluate the safety and antitumour activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, combined with tremelimumab, an anti-CTLA-4 antibody, in patients with stage III/IV non-small cell lung cancer (NSCLC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses how GC4419 may assist in delivering more effective radiation therapy at ASTRO Head and Neck Symposium 2016.

Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses how GC4419 appears to decrease duration of oral mucositis at ASTRO Head and Neck Symposium 2016.

Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses the trial results of Superoxide Dismotase Mimetic GC4419 to Reduce Chemoradiotherapy-induced Oral Mucositis at ASTRO Head and Neck Symposium 2016.

Carryn Anderson, MD of the University of Iowa Carver College of Medicine discusses the GC4419 mechanism of action at ASTRO Head and Neck Symposium 2016.

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS, MRCP(UK), FAMS, from the National Cancer Centre Singapore, Singapore, discusses the development of immunotherapy for patients with hepatocellular carcinoma (HCC), including early promising clinical data with nivolumab, a programmed cell death-1 (PD-1) antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Lisa Shnayder, MD of the University of Kansas Medical Center discusses how free tissue transfer can help intelligibility of speech in tongue and oropharynx defects at ASTRO Head and Neck Symposium 2016.

Lisa Shnayder, MD of the University of Kansas Medical Center discusses the new cost saving technologies for reconstructing a mandible after cancer treatment at ASTRO Head and Neck Symposium 2016.

Lisa Shnayder, MD of the University of Kansas Medical Center discusses the challenges reguarding reconstructing oral cavity defects after treatment at ASTRO Head and Neck Symposium 2016.

Lisa Shnayder, MD of the University of Kansas Medical Center high;lights that there is no clear data HPV increases risk of oral cavity cancer at ASTRO Head and Neck Symposium 2016.

Jessica M. Frakes, MD of Moffitt Cancer Center states that HPV-positive oropharyngeal cancer can be found through imaging and physical exams within six months after treatment at ASTRO Head and Neck Symposium 2016. Press Release: https://www.astro.org/uploadedFiles/Main_Site/News_and_Media/News_Releases/2016/HN16_Frakes.pdf

Jessica M. Frakes, MD of Moffitt Cancer Center discusses why NCCN guidelines may not be best management of HPV+ patients after treatment at ASTRO Head and Neck Symposium 2016.

Thomas Churilla, MD of Fox Chase Cancer Center discusses Uninsured and Medicaid patients with head and neck cancer more likely to present with advanced tumors, experience cancer specific mortality at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses new agents in clinical trials that appear interesting and potentially valuable additions to the therapeutic armamentarium for SCCHN at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses the potential role for PD-1 and PD-L1 monoclonal antibodies in Squamous Cell Head & Neck Carcinomas at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses if biomarkers help select patients more or less likely to benefit from agents targeting EGFR in SCCHN at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses role do for EGFR-TKIs in the future management of SCCHN at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses other LUX-Head & Neck trials are ongoing at this time at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses the results of the LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses how the EGFR monoclonal antibody, Nimotuzumab, differ from cetuximab and panitumumab and If it’s likely to play a therapeutic role in SCCHN at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses the importance of targeting EGFR in Squamous Cell Carcinoma of the Head & Neck at ASTRO Head and Neck Symposium 2016.

Ezra Cohen, MD of the University of California at San Diego discusses the last 5 years of HPV-associated squamous cell carcinoma management at ASTRO Head and Neck Symposium 2016.

Is it really important to mention treatment side effects to your healthcare team? CLL expert Dr. Nicole Lamanna of Columbia University Medical Center and Physician Assistant Jamie Lynn Gibbons of MD Anderson Cancer Center explore nature of treatment-related side effects, what your doctor may be looking for, and steps your healthcare team can make to alleviate symptoms. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating of MD Anderson and Dr. Nicole Lamanna of Columbia University give a thorough description of FISH and CLL profiling, emphasizing the need to get the right test done at the right time to obtain the best targeted therapy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

In February 2016, the FDA placed a full clinical hold on the trials for the MPN treatment pacritinib. To find out more, we reached out to one of the principal investigators for the trial, Dr. Ruben Mesa from the Mayo Clinic in Arizona. Watch as Dr. Mesa helps patients to understand why the FDA places holds on trials from time to time, particularly related to the pacritinib trial. He also shares guidance specifically for patients that may have been on the trial and how they should move forward. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on…

Dr. Keith C. Bible, MD or the Mayo Clinic discusses the clinical benefit rate and duration of response for first and second line therapy in RAI-refractory well-differentiated thyroid cancer at ASTRO Head and Neck Symposium

Dr. Keith C. Bible, MD or the Mayo Clinic discusses how important a target is VEGFR in well-differentiated thyroid cancer at ASTRO Head and Neck Symposium

Dr. Keith C. Bible, MD or the Mayo Clinic discusses standard of care for RAI refractory well-differentiated thyroid cancer at ASTRO Head and Neck Symposium

Dr. Keith C. Bible, MD or the Mayo Clinic discusses tricks to help minimize and prevent adverse events with sorafenib and other TKIs in thyroid cancer at ASTRO Head and Neck Symposium

Dr. Keith C. Bible, MD or the Mayo Clinic discusses targeting genetic abnormalities and signaling pathways for papillary and follicular carcinoma at ASTRO Head and Neck Symposium

Dr. Bhisham Chera, MD of the University of North Carolina Hospitals, Chapel Hill discusses the scientific rationale behind the attempt to de-intensify chemoradiotherapy for HPV-associated Carcinoma at ASTRO Head and Neck Conference.

Dr. Bhishamjit S. Chera, MD of University of North Carolina Hospitals, Chapel Hill, North Carolina gives an overview of a Phase II Trial of De-intensified Chemoradiotherapy for Low-Risk HPV-associated Oropharyngeal Squamous Cell Carcinoma. Purpose To perform a prospective, multi-institutional, phase 2 study of a substantial decrease in concurrent chemoradiation therapy (CRT) intensity as primary treatment for favorable-risk, human papillomavirusassociated oropharyngeal squamous cell carcinoma. Methods and Materials The major inclusion criteria were: (1) T0 to T3, N0 to N2c, M0; (2) human papillomavirus or p16 positive; and (3) minimal/remote smoking history. Treatment was limited to 60 Gy intensity modulated radiation therapy…